Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects | Zendy

Doug J. Bartels | Zendy; Yi Zhou | Zendy; Eileen Z. Zhang | Zendy; Michelle Marcial | Zendy; Randal A. Byrn | Zendy; Thomas Pfeiffer | Zendy; Ann M. Tigges | Zendy; Bambang S. Adiwijaya | Zendy; Chao Lin | Zendy; Ann D. Kwong | Zendy; Tara L. Kieffer | Zendy

Open Access

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

Author(s) -

Doug J. Bartels,

Yi Zhou,

Eileen Z. Zhang,

Michelle Marcial,

Randal A. Byrn,

Thomas Pfeiffer,

Ann M. Tigges,

Bambang S. Adiwijaya,

Chao Lin,

Ann D. Kwong,

Tara L. Kieffer

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/591141

Subject(s) - boceprevir , telaprevir , ns3 , hepatitis c virus , protease , ribavirin , virology , medicine , virus , population , protease inhibitor (pharmacology) , hepatitis c , biology , immunology , viral load , enzyme , biochemistry , environmental health , antiretroviral therapy

The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their effect on clinical response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research